ISDA

Deposition Date 2012-08-03

Release Date 2013-06-19

Last Version Date 2023-09-13

Entry Detail

PDB ID:

4GFO

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

TYK2 kinase (JH1 domain) with 2,6-DICHLORO-N-(2-OXO-2,5-DIHYDROPYRIDIN-4-YL)BENZAMIDE

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.30 Å

R-Value Free:

0.28

R-Value Work:

0.23

R-Value Observed:

0.23

Space Group:

P 65 2 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Non-receptor tyrosine-protein kinase TYK2
Gene (Uniprot):TYK2
Mutations:D1023N
Chain IDs:A
Chain Length:302
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P29597 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

0X2

EDO

GOL

SO4

Primary Citation

Lead identification of novel and selective TYK2 inhibitors.

Liang, J, Tsui, V, Van Abbema, A, Bao, L, Barrett, K, Beresini, M, Berezhkovskiy, L, Blair, W.S, Chang, C, Driscoll, J, Eigenbrot, C, Ghilardi, N, Gibbons, P, Halladay, J, Johnson, A, Kohli, P.B, Lai, Y, Liimatta, M, Mantik, P, Menghrajani, K, Murray, J, Sambrone, A, Xiao, Y, Shia, S, Shin, Y, Smith, J, Sohn, S, Stanley, M, Ultsch, M, Zhang, B, Wu, L.C, Magnuson, S.Show

Eur.J.Med.Chem. 67 175 187 (2013)

PMID: 23867602 DOI: 10.1016/j.ejmech.2013.03.070

Abstact

A therapeutic rationale is proposed for the treatment of inflammatory diseases, such as psoriasis and inflammatory bowel diseases (IBD), by selective targeting of TYK2. Hit triage, following a high-throughput screen for TYK2 inhibitors, revealed pyridine 1 as a promising starting point for lead identification. Initial expansion of 3 separate regions of the molecule led to eventual identification of cyclopropyl amide 46, a potent lead analog with good kinase selectivity, physicochemical properties, and pharmacokinetic profile. Analysis of the binding modes of the series in TYK2 and JAK2 crystal structures revealed key interactions leading to good TYK2 potency and design options for future optimization of selectivity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures